Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer

Conditions

Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer

Trial Timeline

May 1, 2004 → Mar 1, 2011

NCT ID

NCT00154102

About Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) is a phase 3 stage product being developed by Merck for Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00154102. Target conditions include Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer.

What happened to similar drugs?

1 of 3 similar drugs in Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer were approved

Approved (1) Terminated (0) Active (2)

✅Crysvita (burosumab-twza) TreatmentUltragenyx PharmaceuticalApproved

🔄SHR6390 + placeboJiangsu Hengrui MedicinePhase 3

🔄Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine + Paclitaxel, Bevacizumab, liposomal doxorubicin, CapecitabineRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00154102	Phase 3	Completed	May 1, 2004	Mar 1, 2011	Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer

Competing Products

13 competing products in Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer

See all competitors

Product	Company	Stage	Hype Score
HER3-DXd	Daiichi Sankyo	Pre-clinical	26
Erlotinib	Astellas Pharma	Phase 2	27
radio-labeled naquotinib + naquotinib	Astellas Pharma	Phase 1	21
KRN23	Kyowa Kirin	Phase 2	35
SHR6390 + placebo	Jiangsu Hengrui Medicine	Phase 3	44
ABT-414	AbbVie	Pre-clinical	26
Venetoclax + Fulvestrant	Roche	Phase 2	27
Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine + Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine	Roche	Phase 3	40
Palbociclib + Everolimus + Exemestane	Pfizer	Phase 1/2	32
Palifermin	Swedish Orphan Biovitrum	Phase 1/2	24
Crysvita (burosumab-twza) Treatment	Ultragenyx Pharmaceutical	Approved	37
FDX104 (4% Doxycycline)	Vyne Therapeutics	Phase 2	25
ATR-04	Azitra	Phase 1/2	14